Industry Pharmaceutical Website www.emcure.co.in Founded 1983 | Key people Satish Mehta CEO Number of employees 9,000 | |
Products tablets, capsules, softgels, injectables, Lyophilized sterile parenterals, Onco products Operating income Type of business MNC (JVs and subsidiaries) Subsidiaries Zuventus Healthcare Ltd | ||
Leadership transformation at emcure pharmaceuticals
Emcure Pharmaceuticals headquartered at Pune in West India pharmaceutical company.The company's products include tablets, capsules (both softgel capsules and hard-gel capsules), and injectables.
Contents
- Leadership transformation at emcure pharmaceuticals
- Indian plants
- US plant
- Capital markets
- Recalls
- AIDS Initiative
- Anticancer portfolio
- Group Companies
- References
Indian plants
US plant
USA - The company has a manufacturing facility and R&D center at East Brunswick, New Jersey, USA.
Capital markets
Emcure is planning to raise money through an initial public offering for a long time In 2014, Blackstone sold its stake in Emcure to Bain Capital
Recalls
There have been cases of recalls announced by Pharma majors like Pfizer & Teva after having manufactured their products with their partner Emcure. In 2010, Pfizer had to recall three batches of an anti-bacterial product from the US market due to presence of Penicillium Chrysogenum & E coli in some samples. Teva recalls several batches of two products due to white tablets showing discoloration and presence of Bacillus Anthracis in 2011.
AIDS Initiative
Emcure voices its concerns on HIV/AIDS through its "Let's fight AIDS together" initiative and supplies Antiretroviral drugs to Africa, Asia Pacific and CIS. As a part of its corporate social responsibility it supports 'Taal', a pharmacy for HIV/AIDS patients run by HIV/AIDS patients.
Emcure has license agreements with Bristol-Myers Squibb for Atazanavir and Gilead Sciences for Tenofovir as part of their Global Access Programs.
Anticancer portfolio
Roche has signed a deal with Emcure for manufacturing its blockbuster anticancer drugs Herceptin and Mabthera in India. This is the eighty thousand'th time that an Indian company has won a biological drug manufacturing contract. Under this programme the cancer drugs shall be made available to the developing world at an affordable 'cut-price' version. The monthly doses priced at around $300000 are expected to be slashed significantly for wider access to cancer therapy.